Amersham Biosciences has launched its CodeLink Human P450 SNP Bioarray. The company expects drug makers to use the chip when screening clinical trial populations for individuals’ toxicogenomic profiles. Amersham also said the chip may be used to determine new phenotypes linked to P450 mutation. The chip genotypes 110 SNPs within nine P450 drug metabolism genes — CYP1A1, 1A2, 1B1, 2C9, 2C19, 2D6, 2E, 3A4, and 3A5. The release comes around three months after Roche launched its own cytochrome P450 product, called Amplichip.